Individual pharmacodynamic parameters of clevidipine obtained by fitting a two-compartment, linked sigmoid Emax PK/PD model following i.v. clevidipine infusion in anesthetized dogs at three different dose rates (n = 6)
| Dog | Emax | EC50 | γ | T1/2ke0 |
|---|---|---|---|---|
| % | nmol/L | s | ||
| 5 (F) | 39.2 | 116.7 | 0.8 | 34 |
| 8 (M) | 26.6 | 45.0 | 1.5 | 14 |
| 11 (M) | 41.2 | 70.5 | 0.9 | 25 |
| 18 (M) | 50.2 | 129.3 | 1.7 | 141 |
| 19 (M) | 22.0 | 20.5 | 3.3 | 12 |
| 24 (F) | 50.6 | 127.5 | 0.9 | 55 |
| Mean | 38.3 | 84.9 | 1.5 | 47 |
| Median | 40.2 | 93.6 | 1.2 | 30 |
| S.D. | 11.9 | 46.3 | 0.9 | 49 |
| C.V.% | 31.0 | 54.6 | 62.3 | 104 |
F, female; M, male; C.V.%, coefficient of variation.